MedTrace Logo

Effect of Sitagliptin on Graft Function Following Islet Transplantation

NCT00853944 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-10-30

No results posted yet for this study

Summary

Islet transplantation requires a large number of islets required to achieve insulin independence and the function of the transplanted islets progressively declines over time. Evidence from animal studies and human islets in culture suggests that increasing GLP-1 levels could help with both of these problems. This study is designed to test this hypothesis using sitagliptin in a randomized clinical trial.

Conditions

  • Islet Transplantation

Interventions

DRUG

sitagliptin

Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study

Sponsors & Collaborators

Principal Investigators

  • David M. Thompson, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2013-11-01
Completion
2013-11-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00853944 on ClinicalTrials.gov